The historical rank and industry rank for Greenwich LifeSciences's Price-to-Free-Cash-Flow or its related term are showing as below:
GLSI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.68 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -60.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -132.90% per year.
During the past 6 years, Greenwich LifeSciences's highest 3-Year average Free Cash Flow per Share Growth Rate was -60.90% per year. The lowest was -221.40% per year. And the median was -171.40% per year.
Greenwich LifeSciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for Greenwich LifeSciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Greenwich LifeSciences's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Greenwich LifeSciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Price-to-Free-Cash-Flow falls into.
Greenwich LifeSciences's Share Price of today is $13.08. Greenwich LifeSciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Greenwich LifeSciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your 